CoChat

Considerations for treatment duration in responders to immune checkpoint inhibitors

Open access

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients with metastatic melanoma, a condition that at the time was incurable, little attention was initially paid to how much therapy would be needed for a durable response. As the early immunotherapy trials have matured past 10 years, a significant per cent of patients have demonstrated durable responses; it is now time to determine whether patients have been overtreated, and if durable remissions can still be achieved with less therapy, limiting the physical and financial toxicity associated with years of treatment. Well-designed trials are needed to identify optimal duration of therapy, and to define biomarkers to predict who would benefit from shorter courses of immunotherapy. Here, we outline key questions related to health, financial and societal toxicities of over treating with ICI and present four unique clinical trials aimed at exposing criteria for early cessation of ICI. Taken together, there is a serious liability to overtreating patients with ICI and future work is warranted to determine when it is safe to stop ICI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-001901

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Patients receiving immune checkpoint inhibitors without progressive disease are treated for an undefined period, which can extend several years and may impose both financial and physical toxicity. Clinical trials are needed to determine criteria that would allow potential early cessation and monitoring thus eliminating both financial and physical toxicities. CR, complete response; ctDNA, circulating tumor DNA; PR, partial response; SD, stable disease.
Figure 1 Patients receiving immune checkpoint inhibitors without progressive disease are treated for an undefined period, which can extend several years and may impose both financial and physical toxicity. Clinical trials are needed to determine criteria that would allow potential early cessation and monitoring thus eliminating both financial and physical toxicities. CR, complete response; ctDNA, circulating tumor DNA; PR, partial response; SD, stable disease.CC BY · PubMed Central
Figure 2 Ongoing prospective clinical trials to determine criteria for early discontinuation of immune checkpoint inhibitors. CR, complete response; MTR, maximal tumor response; PR, partial response; SD, stable disease.
Figure 2 Ongoing prospective clinical trials to determine criteria for early discontinuation of immune checkpoint inhibitors. CR, complete response; MTR, maximal tumor response; PR, partial response; SD, stable disease.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 137

Metadata

Authors
Marron, T. U., Ryan, A. E., Reddy, S. M., Kaczanowska, S., Younis, R. H., Thakkar, D., Zhang, J., Bartkowiak, T., Howard, R., Anderson, K. G., Olson, D., Naqash, A. R., Patel, R. B., Sachdev, E., Rodriguez-Ruiz, M. E., Sheffer, M., Church, S., Fuhrman, C., Overacre-Delgoffe, A., Nguyen, R., Florou, V., Thaxton, J. E., Aggen, D. H., & Guerriero, J. L.
Affiliations
  • Icahn School of Medicine at Mount Sinai (US)
  • National University of Ireland (IE)
  • The University of Texas Southwestern Medical Center (US)
  • National Institutes of Health (US)
  • University of Maryland, Baltimore (US)
  • Hummingbird Scientific (United States) (US)
  • Johns Hopkins University (US)
  • Vanderbilt University (US)
  • Moffitt Cancer Center (US)
  • University of Washington (US)
  • University of Chicago (US)
  • University of Pittsburgh (US)
  • University of Southern California (US)
  • Clinica Universidad de Navarra (ES)
  • Dana-Farber Cancer Institute (US)
  • Transitional Sciences, NanoString Technologies Inc, Seattle, Washington, USA
  • Nanostring Technologies (United States) (US)
  • National Cancer Institute (US)
  • Huntsman Cancer Institute (US)
  • Medical University of South Carolina (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Brigham and Women's Hospital (US)
Corresponding author
Guerriero, Jennifer L
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2021-03
Volume
9
Issue
3
Pages
e001901
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3134221665
Cited by
137
References
47
Citations by year
2026: 13 · 2025: 31 · 2024: 21 · 2023: 36 · 2022: 31 · 2021: 5
FWCI
2.81
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Greater South Information System
Funders
SITC SPARKATHON
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
immune checkpoint inhibitors, treatment duration, durable response, overtreatment, financial toxicity, health-related quality of life, treatment response biomarkers, early clinical trials, metastatic melanoma, immunotherapy toxicity
MeSH terms
Immune Checkpoint Inhibitors, Clinical Trials as Topic, Drug Administration Schedule, Humans, Neoplasms, Risk Factors, Time Factors, Treatment Outcome, Risk Assessment, Evidence-Based Medicine, Patient Safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Considerations for treatment duration in responders to immune checkpoint inhibitors. https://app.cochat.ai/papers/10.1136/jitc-2020-001901
The paper
Marron, T. U., Ryan, A. E., Reddy, S. M., Kaczanowska, S., Younis, R. H., Thakkar, D., Zhang, J., Bartkowiak, T., Howard, R., Anderson, K. G., Olson, D., Naqash, A. R., Patel, R. B., Sachdev, E., Rodriguez-Ruiz, M. E., Sheffer, M., Church, S., Fuhrman, C., Overacre-Delgoffe, A., . . . Guerriero, J. L. (2021). Considerations for treatment duration in responders to immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-001901

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.